Trial Profile
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Ribociclib (Primary) ; Anastrozole; Exemestane; Letrozole; Tamoxifen
- Indications Adenocarcinoma; Early breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Adverse reactions
- Acronyms EarLEE-1
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 23 Jan 2021 This trial has been Discontinued in Netherlands, according to European Clinical Trials Database record.
- 26 Oct 2020 This trial has been Discontinued in Czech Republic, according to European Clinical Trials Database record.
- 02 Oct 2020 This trial has been discontinued in Netherlands, according to European Clinical Trials Database record.